Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEP + Dasatinib + Azacitidine in First-line AITL
NCT07046182Phase 4Active, not recruiting
- Sponsor
- Zhengzhou University
- Start
- Oct 2023
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dasatinib, azacitidine in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Zhengzhou University. Started Oct 2023; status: active, not recruiting.
02
Drugs
dasatinibazacitidine
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT07046182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046182.